Home › Funds › GILDER GAGNON HOWE & CO LLC › ALNY
GILDER GAGNON HOWE & CO LLC position in ALNY
ALNYLAM PHARMACEUTICALS INC · Health Care
GILDER GAGNON HOWE & CO LLC reported holding 228,065 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$56.3M, representing 0.60% of its reported portfolio and ranking #46 among its reported holdings. GILDER GAGNON HOWE & CO LLC has disclosed ALNY holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How GILDER GAGNON HOWE & CO LLC's ALNY position evolved
GILDER GAGNON HOWE & CO LLC first disclosed a stake in ALNY in Q3 2023 at 594,979 shares (US$105.4M). The position peaked in Q3 2025 at 329,321 shares, worth US$150.2M. Across 13 filings, GILDER GAGNON HOWE & CO LLC increased the stake 0 time(s), trimmed it 12 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 228,065 shares valued at US$56.3M — a reduction of -40,986 shares quarter over quarter.. Notable position changes include a 31% trim in Q1 2024 (shares rose 63% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 594.98K | $105.37M | New |
| Q4 2023 | 587.04K | $112.37M | Reduce |
| Q1 2024 | 405.17K | $60.55M | Reduce |
| Q2 2024 | 398.62K | $96.86M | Reduce |
| Q3 2024 | 383.99K | $105.61M | Reduce |
| Q4 2024 | 365.46K | $86.00M | Reduce |
| Q1 2025 | 345.57K | $93.31M | Reduce |
| Q2 2025 | 337.09K | $109.92M | Reduce |
| Q3 2025 | 329.32K | $150.17M | Reduce |
| Q4 2025 | 319.31K | $126.97M | Reduce |
| Q1 2026 | 280.09K | $92.67M | Reduce |
| Q2 2026 | 269.05K | $80.99M | Reduce |
| Q3 2026 | 228.06K | $56.27M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALNY and 13F data
ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 30 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$2.47B), Baillie Gifford & Co (US$1.36B), Orbis Allan Gray Ltd (US$597.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALNY
- T. Rowe Price Investment Management, Inc. 10.01M sh · $2.47B · Q3 2026
- Baillie Gifford & Co 5.49M sh · $1.36B · Q3 2026
- Orbis Allan Gray Ltd 2.42M sh · $597.40M · Q3 2026
- TWO SIGMA ADVISERS, LP 1.13M sh · $450.36M · Q4 2025
More on GILDER GAGNON HOWE & CO LLC
FAQ
How long has GILDER GAGNON HOWE & CO LLC held ALNY?
GILDER GAGNON HOWE & CO LLC has disclosed ALNY holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is GILDER GAGNON HOWE & CO LLC's current position in ALNY?
As of Q3 2026, GILDER GAGNON HOWE & CO LLC holds 228.06K shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $56.27M, representing 0.60% of its reported portfolio and ranking #46.
Has GILDER GAGNON HOWE & CO LLC been buying or selling ALNY?
In the latest 13F filing (Q3 2026), GILDER GAGNON HOWE & CO LLC reduced its position in ALNY. The position peaked in Q3 2025 at 329.32K shares.
Which other funds hold ALNY?
Other major institutional holders of ALNY include T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, Orbis Allan Gray Ltd, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.